Government proposes immediate suspension of manufacturing licences of substandard drugs

In a move aimed at strengthening drug safety, the Ministry of Health and Family Welfare introduced a draft amendment that would allow immediate suspension of licences for manufacturers found producing substandard medicines. The proposal follows a series of high‑profile recalls and reports of poor‑quality drugs that have raised public health concerns across the country. Under the new rules, regulatory authorities can issue a suspension order as soon as a violation is confirmed, preventing the company from continuing production until the issue is resolved.

The amendment also outlines a clear pathway for corrective measures, stating that a suspended licence will remain in effect until the manufacturer demonstrates compliance with prescribed standards. Companies will be required to submit a detailed corrective action plan, undergo independent verification, and receive clearance from the drug regulator before the suspension can be lifted. This approach is intended to ensure that manufacturers address the root causes of quality lapses rather than merely appealing the suspension.

Stakeholders, including pharmaceutical industry bodies and consumer advocacy groups, have expressed mixed reactions. While industry representatives warn that rapid suspension could disrupt supply chains and affect drug availability, public health advocates argue that the amendment is a necessary step to protect patients from unsafe medicines. The government has indicated that it will seek feedback from all parties before finalising the amendment, with an eye on balancing safety with the need to maintain a steady supply of essential drugs.